Literature DB >> 22203473

Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.

C G Stoehr1, R Stoehr, A Hartmann, F Hofstaedter, K Junker, H Blaszyk, W F Wieland, W Otto, S Denzinger, B Walter.   

Abstract

BACKGROUND: Somatic point mutations in the fibroblast growth factor receptor 3 (FGFR3) gene have been identified in certain types of urological cancers, especially urothelial carcinoma of the bladder and the renal pelvis, and could be correlated with a favourable outcome. However, comprehensive data on the FGFR3 mutation status in renal cell carcinoma (RCC) are still missing.
METHODS: In order to investigate a possible role for FGFR3 mutations in renal cell carcinogenesis, we performed a sequence-based mutational analysis of FGFR3 in 238 primary RCC. The cohort obtained the common RCC subtypes including 101 clear cell, 50 papillary and 68 chromophobe RCC specimens. The analysed regions encompassed all FGFR3 point mutations previously described in epithelial tumours and other noncutaneous epithelial malignancies.
RESULTS: No mutations were detected in any renal tumour type examined, and all cases showed wild-type sequence.
CONCLUSION: Our results argue against an involvement of mutational activation of FGFR3 in the development of RCC. A recently described cystic renal dysplasia in a patient with thanatophoric dysplasia type 1 due to a germ line FGFR3 mutation might portend to an involvement of mutational FGFR3 activation in renal cyst formation, but this speculation needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203473     DOI: 10.1007/s00432-011-1130-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  15 in total

Review 1.  Role of fibroblast growth factor receptor signaling in kidney development.

Authors:  Carlton M Bates
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

2.  A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.

Authors:  Johanna M M van Oers; Irene Lurkin; Antonius J A van Exsel; Yvette Nijsen; Bas W G van Rhijn; Madelon N M van der Aa; Ellen C Zwarthoff
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

3.  FGFR3 mutation in thanatophoric dysplasia type 1 with bilateral cystic renal dysplasia: coincidence or a new association?

Authors:  P Prontera; A Sensi; G Pilu; M Baldi; M Baffico; R Bonasoni; E Calzolari
Journal:  Genet Couns       Date:  2006

4.  Multiple fibroblast growth factors support growth of the ureteric bud but have different effects on branching morphogenesis.

Authors:  J Qiao; K T Bush; D L Steer; R O Stuart; H Sakurai; W Wachsman; S K Nigam
Journal:  Mech Dev       Date:  2001-12       Impact factor: 1.882

5.  Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma.

Authors:  Elisabetta Cenni; Francesca Perut; Donatella Granchi; Sofia Avnet; Ilaria Amato; Maria Luisa Brandi; Armando Giunti; Nicola Baldini
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

6.  High-throughput oncogene mutation profiling in human cancer.

Authors:  Roman K Thomas; Alissa C Baker; Ralph M Debiasi; Wendy Winckler; Thomas Laframboise; William M Lin; Meng Wang; Whei Feng; Thomas Zander; Laura MacConaill; Laura E Macconnaill; Jeffrey C Lee; Rick Nicoletti; Charlie Hatton; Mary Goyette; Luc Girard; Kuntal Majmudar; Liuda Ziaugra; Kwok-Kin Wong; Stacey Gabriel; Rameen Beroukhim; Michael Peyton; Jordi Barretina; Amit Dutt; Caroline Emery; Heidi Greulich; Kinjal Shah; Hidefumi Sasaki; Adi Gazdar; John Minna; Scott A Armstrong; Ingo K Mellinghoff; F Stephen Hodi; Glenn Dranoff; Paul S Mischel; Tim F Cloughesy; Stan F Nelson; Linda M Liau; Kirsten Mertz; Mark A Rubin; Holger Moch; Massimo Loda; William Catalona; Jonathan Fletcher; Sabina Signoretti; Frederic Kaye; Kenneth C Anderson; George D Demetri; Reinhard Dummer; Stephan Wagner; Meenhard Herlyn; William R Sellers; Matthew Meyerson; Levi A Garraway
Journal:  Nat Genet       Date:  2007-02-11       Impact factor: 38.330

7.  Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.

Authors:  Christian Hafner; Johanna M M van Oers; Thomas Vogt; Michael Landthaler; Robert Stoehr; Hagen Blaszyk; Ferdinand Hofstaedter; Ellen C Zwarthoff; Arndt Hartmann
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

Review 8.  Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications.

Authors:  M V Cronauer; W A Schulz; H-H Seifert; R Ackermann; M Burchardt
Journal:  Eur Urol       Date:  2003-03       Impact factor: 20.096

9.  Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure.

Authors:  Pascal Hajj; Sophie Ferlicot; Walid Massoud; Ayman Awad; Yacine Hammoudi; Bernard Charpentier; Antoine Durrbach; Stéphane Droupy; Gérard Benoît
Journal:  Urology       Date:  2009-07-18       Impact factor: 2.649

10.  Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.

Authors:  Xuewen Song; Valeria Di Giovanni; Ning He; Kairong Wang; Alistair Ingram; Norman D Rosenblum; York Pei
Journal:  Hum Mol Genet       Date:  2009-04-03       Impact factor: 6.150

View more
  4 in total

1.  Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.

Authors:  Christine Spiegelberg; Johannes Giedl; Nadine T Gaisa; Anja Rogler; Marc-Oliver Riener; Thomas Filbeck; Maximilian Burger; Petra Ruemmele; Arndt Hartmann; Robert Stoehr
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

2.  Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.

Authors:  Michelangelo Fiorentino; Elisa Gruppioni; Francesco Massari; Francesca Giunchi; Annalisa Altimari; Chiara Ciccarese; Davide Bimbatti; Aldo Scarpa; Roberto Iacovelli; Camillo Porta; Sarhadi Virinder; Giampaolo Tortora; Walter Artibani; Riccardo Schiavina; Andrea Ardizzoni; Matteo Brunelli; Sakari Knuutila; Guido Martignoni
Journal:  Oncotarget       Date:  2017-01-31

3.  YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.

Authors:  Wei Li; Kun Ye; Xurui Li; Xinlin Liu; Mou Peng; Fang Chen; Wei Xiong; Yinhuai Wang; Liang Zhu
Journal:  J Exp Clin Cancer Res       Date:  2022-08-17

4.  Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.

Authors:  Linda Köhn; Ulrika Svenson; Börje Ljungberg; Göran Roos
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015 May-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.